Proudly supported by Diabetes NSW & ACT and Diabetes Queensland.
Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are oral medications that promote glucose excretion in the urine for the
treatment of type 2 diabetes. Note that SGLT2i are not approved for use in the management of type 1 diabetes in Australia or
New Zealand, although they are sometimes used off-label in this setting.
Click below for the full update.